William Blair Initiates on Insulet (PODD) With Outperform and Says the Valuation Gap Is Hard to Justify

Insulet Corporation (NASDAQ:PODD) is one of the best medical technology stocks to buy right now. On May 20, William Blair analyst Steve Lichtman assumed coverage of Insulet Corporation (NASDAQ:PODD) with an Outperform rating.

Lichtman argued that Insulet’s steep selloff has created an appealing entry point despite risks to its near‑term growth outlook. The analyst highlighted that the company’s valuation looks attractive compared to peers, especially given its stronger revenue trajectory.

Cherries/Shutterstock.com

Nevertheless, the analyst flagged the threat of increased competition. He noted that rival device makers are pushing into Insulet’s pharmacy distribution channel and the tubeless pump market where Omnipod holds a dominant position. The analyst added that there is quite an amount of uncertainty around how much of the type 2 diabetes patient population Insulet can realistically capture, given that GLP-1 drugs like Ozempic and Mounjaro are increasingly managing these patients without requiring insulin delivery devices.

Despite those concerns, Lichtman concluded that the bull case is stronger. He pointed to an ongoing US salesforce expansion that should widen Insulet’s commercial reach domestically as one of key growth catalysts that could drive the stock higher. The other catalysts are a rich product development pipeline and continued international market penetration where Omnipod still has significant room to grow.

Insulet Corporation (NASDAQ:PODD) is a medical technology company that develops and manufactures wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, a tubeless automated insulin delivery device that integrates with continuous glucose monitoring systems to help patients manage blood sugar levels more effectively.

READ NEXT: 7 Best Augmented Reality Penny Stocks to Buy and 10 Best Gene Therapy Stocks to Buy in 2026.

Disclosure: None. Follow Insider Monkey on Google News.